The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
Public ClinicalTrials.gov record NCT03364335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study of Effects of Two Fixed-dose Leucine-sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine-sildenafil-metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24).
Study identification
- NCT ID
- NCT03364335
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 267 participants
Conditions and interventions
Conditions
Interventions
- Leu Sil 1.0mg Drug
- Leu Sil 4.0mg Drug
- Leu Met Sil 1.0mg Drug
- Leu Met Sil 4.0mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2018
- Primary completion
- Aug 5, 2018
- Completion
- Aug 16, 2018
- Last update posted
- Aug 20, 2019
2018
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AMR | Mobile | Alabama | 36608 | — |
| Catalina Research Institute | Montclair | California | 91763 | — |
| Northern California Research | Sacramento | California | 95821 | — |
| ACR | Meridian | Idaho | 83642 | — |
| Synexus | Chicago | Illinois | 60602 | — |
| Pennington Biomedical Research Center | Baton Rouge | Louisiana | 70808 | — |
| Clinical Trials Management | Metairie | Louisiana | 70006 | — |
| Synexus | St Louis | Missouri | 63141 | — |
| AMR | Las Vegas | Nevada | 89119 | — |
| Rapid Medical Research | Cleveland | Ohio | 44122 | — |
| Medical Research South | Charleston | South Carolina | 29407 | — |
| Premier | Clarksville | Tennessee | 37040 | — |
| Synexus | Dallas | Texas | 75234 | — |
| Synexus | San Antonio | Texas | 78229 | — |
| ACR | Jordan | Utah | 84088 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03364335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2019 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03364335 live on ClinicalTrials.gov.